<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Gryphon bio &#8211; UF Innovate</title>
	<atom:link href="https://innovate.research.ufl.edu/tag/gryphon-bio/feed/" rel="self" type="application/rss+xml" />
	<link>https://innovate.research.ufl.edu</link>
	<description>Building business on innovation</description>
	<lastBuildDate>Tue, 12 Aug 2025 04:44:33 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png</url>
	<title>Gryphon bio &#8211; UF Innovate</title>
	<link>https://innovate.research.ufl.edu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel To Monitor Treatment Journey for Patients With Traumatic Brain Injury and Alzheimer’s</title>
		<link>https://innovate.research.ufl.edu/gryphon-bio-blood-biomarker-panel/</link>
		
		<dc:creator><![CDATA[sooyoungryu]]></dc:creator>
		<pubDate>Tue, 14 Jan 2025 00:00:00 +0000</pubDate>
				<category><![CDATA[News Brief]]></category>
		<category><![CDATA[Tech Licensing]]></category>
		<category><![CDATA[UF Innovate]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[blood biomarker]]></category>
		<category><![CDATA[Gryphon bio]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[traumatic brain injury]]></category>
		<guid isPermaLink="false">https://scaddev1.com/gryphon-bio-blood-biomarker-panel/</guid>

					<description><![CDATA[UF Innovate's funding institution Gryphon Bio, Inc. is pursuing observational clinical studies with U.S. and international partners to validate a novel blood biomarker panel for early detection and monitoring of TBI and Alzheimer’s disease.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">UF Innovate&#8217;s funding institution Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and international clinical sites to demonstrate the benefits of a novel panel of blood biomarkers for early detection and monitoring of traumatic brain injury (TBI) and Alzheimer&#8217;s disease (AD). Combined with known risk factors, such as age and genetic variants, the Gryphon Bio studies are potential game-changers to monitor the treatment journey and develop novel therapeutics for active-duty soldiers, Veterans, adults, and children worldwide who suffer from this devastating disease.</p>



Read more about <a href="https://www.prnewswire.com/news-releases/gryphon-bio-inc-pioneers-novel-blood-biomarker-panel-to-monitor-treatment-journey-for-patients-with-traumatic-brain-injury-and-alzheimers-302349637.html">Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel To Monitor Treatment Journey for Patients With Traumatic Brain Injury and Alzheimer’s. </a>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
